The incidence and prevalence of patients with heart failure (HF) is steadily increasing along with advancing age in Japan.\(^1\,^2\) Regardless of recent advances in the control of HF, including medical treatments and device therapies, HF is still a grievous clinical problem due to high mortality and rehospitalization rates.\(^3\,^4\,^5\,^6\) Clinical congestion is one of the most common conditions observed in patients with acute decompensated HF. In addition, prolonged congestion leads to longer hospitalization and worse prognoses.\(^7\,^8\) Therefore, clinical guidelines suggest rapid evaluation and management of congestion in patients with acute HF.\(^9\) Medical treatment, including the use of diuretics and/or vasodilators and non-invasive positive pressure ventilation, has been established and should be conducted along a time base.\(^9\) Although the Efficacy of Vasopressin Antagonism in Heart Failure Outcomes Study with Tolvaptan (EVEREST) trial has identified that residual congestion status at the time of hospital discharge resulted in worse outcomes,\(^10\) an ideal solution for the treatment of congestion, including the speed of removal during the acute phase after emergency admission in patients with acute decompensated HF, is not likely.

Thus, the present study investigated whether a change in clinical congestion during index hospitalization contributes to improvements in 1-year mortality and rehospitalization rates among hospitalized acute decompensated HF patients.

**Methods**

**Study Population**

The study population comprised 453 individuals who were hospitalized for acute decompensated HF in Kasugai Municipal Hospital from July 2015 to March 2017. Patients transferred from other hospitals and those who...
were receiving HF therapy during hospitalization due to other diseases were excluded from the study. In addition, patients undergoing hemodialysis, those with HF caused by acute myocardial infarction, or those who died within 2 days of hospital admission were excluded. For patients with rehospitalization due to HF within 1 year of the first hospitalization, the first eligible hospitalization was evaluated.

The study protocol complied with the Declaration of Helsinki and was approved by the Committees on Ethics of Kasugai Municipal Hospital (Reference no. 355); the collection of congestion scores was also approved. Each patient was offered the opportunity to opt out of the study (see https://www.hospital.kasugai.aichi.jp/byouin/torikumi/rinsho/rinri/documents/rinri_6.pdf [in Japanese]). No patient opted-out of the study, so the study was performed on consecutive patients.

Definitions
HF was defined according to the American College of Cardiology/American Heart Association guidelines with the signs and symptoms of HF and confirmed left ventricular systolic or diastolic dysfunction. The congestion score was determined according to the EVEREST trial and consisted of the signs and symptoms of HF, including dyspnea, fatigue, orthopnea, jugular venous distention, rales, and pedal edema. The composite congestion score was evaluated using a 4-point scale ranging from 0 to 3 for each value and calculated by summing each score. The congestion score was calculated at admission, at 08:00 hours on Day 3 (>32 but <56 g/dL for males and ≤32 but >24 g/dL for females), and at 08:00 hours on the day of discharge (Fig. 1). The optimal cut-off value for the rate of improvement in congestion scores from admission to Day 3 was determined using the receiver operating characteristic curve method for predicting 1-year mortality.

Anemia was defined as hemoglobin levels <13 g/dL for males and <12 g/dL for females according to World Health Organization (WHO) recommendations. Causes of death were divided into cardiovascular and non-cardiovascular. Cardiovascular death was defined as any death due to proximate cardiac cause (e.g., myocardial infarction, HF, lethal arrhythmia), whereas non-cardiovascular death was defined as any death from malignancy, respiratory, infectious, or renal causes.

Data Collection
Clinical characteristics (age, sex, height, weight, previous medical history, New York Heart Association functional classification, etiology of HF, non-cardiac comorbidities, vital signs, and laboratory data), in-hospital treatment, medications at discharge, and 1-year mortality were assessed. Echocardiographic data at discharge were also collected.

Statistical Analysis
Categorical variables are presented as percentages, whereas continuous variables are presented as the median with interquartile range (IQR) or as the mean ± SD. Categorical variables were compared by the Chi-squared test. The distribution of continuous variables was examined using the Shapiro-Wilk test; normally distributed variables were compared using the unpaired Student’s t-test, whereas variables that were not normally distributed were compared using the Mann-Whitney U-test. Multivariable logistic regression analysis was performed to identify independent predictors of 1-year mortality. Notably, all variables that were statistically significant on univariate analysis were considered as potential covariates: P-values, odds ratios (ORs), and 95% confidence intervals (CI) were calculated. A P-value of <0.05 was considered statistically significant. Statistical significance was examined using 2-sided tests performed in JMP version 13 (SAS Institute, Cary, NC, USA).

Results
The characteristics of the study subjects (n = 453) are given in Table 1. The median age was 81 years (IQR 75–87 years) and 54.1% of the subjects were male. The congestion scores at hospital admission, on Day 3, and at discharge were 11 (IQR 8–14), 2 (IQR 1–5), and 0, respectively (Table 2). At the 1-year time point, the cumulative incidence of all-cause mortality was 22.7% (n = 103): 15.9% of subjects (n = 72) had died from cardiovascular causes, 6.8% of subjects (n = 31) had died from non-cardiovascular causes, and 20.5% (n = 93) were rehospitalized due to HF (Table 2).

Congestion scores on Day 3 and subjects with residual congestion (defined as those with congestion scores ≥3 on Day 3) were significantly (P < 0.05) greater in subjects who died within 1 year than in those who were alive. However, there were no significant differences in congestion scores at admission and at discharge between these 2 groups. In addition, the rate of improvement in congestion scores (71.4% vs. 43.7%) and the reduction in congestion scores from admission to Day 3 (81.3% vs. 58.3%) were significantly (P < 0.05) greater in subjects who were alive at 1 year than in those who had died (Table 3).

Univariate analysis revealed that both the congestion score at Day 3 and the rate of improvement in congestion scores from admission to Day 3 were related to 1-year all-cause mortality (P < 0.001). The multivariable Cox regression model identified age and left ventricular ejection fraction (LVEF) as significant independent predictors of
Table 1. Characteristics of Study Subjects (n=453)

| Age (years) | 81 (75–87) |
| Males/females (%) | 54.1/45.9 |
| Current or former smoker (%) | 47.5 |
| BMI (kg/m²) | 21.7 (19.1–24.6) |
| Dyslipidemia (%) | 22.1 |
| T2D (%) | 36.2 |
| Hypertension (%) | 68.6 |
| Reduced (<60 mL/min/1.73 m²) eGFR (%) | 78.1 |
| Atial fibrillation or atrial flutter (%) | 33.3 |
| Previous MI (%) | 23.6 |
| Previous stroke (%) | 12.8 |
| Previous HF hospitalization (%) | 34.9 |
| Ischemic etiology (%) | 31.2 |

Initial evaluation
- SBP (mmHg): 147 (124–176)
- DBP (mmHg): 83 (68–102)
- Heart rate (beats/min): 93 (77–115)
- NYHA functional class (%): III 38.8, IV 61.2
- Jugular venous distension (%): 78.2
- Blood urea nitrogen (mg/dL): 25.4 (18.7–35.2)
- Sodium (mEq/L): 140 (137–142)
- Potassium (mEq/L): 4.2 (3.8–4.6)
- Creatinine (mg/dL): 1.21 (0.88–1.73)
- Uric acid (mg/dL): 7.3 (5.7–8.8)
- Albumin (mg/dL): 3.5 (3.2–3.8)
- TC (mg/dL): 154 (132–180)
- HDL (mg/dL): 629 (310–1,156)
- Hb (mg/dL): 11.2 (9.9–13.1)
- LVEF (%) | 50 (35–64)
- LVEF categories (%): LVEF <40% 31.1, 40%≤LVEF<50% 16.8, LVEF ≥50% 52.1

Categorical variables are given as percentages, whereas continuous variables are given as the median (interquartile range). BMI, body mass index; BNP, brain natriuretic peptide; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration rate; Hb, hemoglobin; HF, heart failure; LVEF, left ventricular ejection fraction; MI, myocardial infarction; NYHA, New York Heart Association; SBP, systolic blood pressure; T2D, type 2 diabetes; TC, total cholesterol.

Table 2. In-Hospital Treatment and Outcomes (n=453)

| In-hospital treatment | Values |
|-----------------------|--------|
| Intravenous drug therapy | 453 (96.0) |
| Diuretics | 268 (59.2) |
| Isosorbide dinitrate and/or nitroglycerin | 259 (57.2) |
| Carperitide | 151 (33.4) |
| Inotropes | 76 (16.7) |

Non-invasive positive pressure ventilation 97 (21.4)

Medication at discharge
- Loop diuretics 362 (88.1)
- Furosemide-equivalent dose (mg) 40 (20–40)
- β-blocker 209 (50.9)
- ACEI or ARB 268 (59.2)
- Aldosterone blocker 252 (56.3)
- Statin 135 (52.8)
- Nitrites 37 (8.0)
- Antiplatelet drugs 158 (38.4)

Congestion score (points)
- At admission 11 (8–14)
- On hospital Day 3 2 (1–5)
- At discharge 0

Hospital length of stay (days)
- In-hospital stay 16 (11–24)
- 1-year outcomes
  - Mortality 103 (22.7)
  - Cardiovascular mortality 72 (15.9)
  - Non-cardiovascular mortality 31 (6.8)
  - Rehospitalization due to heart failure 93 (20.5)

Categorical variables are given as percentages, whereas continuous variables are given as the median (interquartile range). ACEI, angiotensin-converting enzyme inhibitor; ARB, angiotensin II receptor blocker.

1-year all-cause mortality and cardiovascular mortality (Table 4). Therefore, we compared Kaplan-Meier survival curves for patients based on LVEF using the log-rank test. Patients were divided into three groups based on LVEF (<40%, 40%≤LVEF<50%, and ≥50%). Event-free survival (either 1-year all-cause mortality or cardiovascular mortality) was significantly higher in subjects with and LVEF ≥50% (P<0.001; Figure 2). We further examined prognostic values by calculating multivariable-adjusted hazard ratios (HRs) for associations of residual congestion (score at Day 3 ≥3) and the rate of improvement from admission to Day 3 (cut-off value 64%) and prognostic variables identified by the univariate Cox regression model (age, body mass index, systolic blood pressure, potassium and albumin concentrations, the prevalence of anemia and hypertension, LVEF, ischemic etiology, and previous HF hospitalization). Relative risk of 1-year all-cause mortality was higher in subjects with residual congestion and lesser improvement (<64%) than in those with residual congestion and greater improvement (≥64%; adjusted [a] HR 2.33, 95% CI 1.11–4.91, P=0.025) or resolved congestion (score at Day 3 <3; aHR 2.17, 95% CI 1.30–3.63, P=0.003; Table 5; Figure 3). Similar analysis revealed a significant relationship between cardiovascular mortality and both congestion score at Day 3 and the rate of improvement from admission to Day 3. Combined predictive values of residual congestion and lesser improvement with adjustment for prognostic variables identified by the univariate Cox regression model (age, body mass index, systolic blood pressure, potassium and albumin concentrations, the prevalence of anemia, reduced estimated glomerular filtration rate [eGFR], and hypertension, LVEF, ischemic etiology, and previous HF hospitalization) were higher than those for residual congestion and higher improvement (aHR 3.04, 95% CI 1.15–8.03, P=0.025), or resolved congestion (aHR 3.17, 95% CI 1.65–6.11, P<0.001; Table 5). Multivariable Cox regression analysis revealed that age, serum potassium, the prevalence of anemia and reduced eGFR, LVEF, and previous HF hospitalization were significantly and independently associated with rehospitalization due to HF. However, there was no relationship between the congestion score at Day 3 or the rate of improvement from admission to Day 3 and rehospitalization due to HF.
Given the possibility of B-type natriuretic peptide (BNP)-guided therapy, we evaluated BNP concentrations across the 3 groups (Supplementary Table). The median admission BNP concentration (pg/mL) was 599 (IQR 259–1,046), 627 (IQR 316–1,033), and 694 (IQR 415–1,482) for patients with resolved congestion, residual congestion with improvement, and residual congestion without improvement, respectively (P=0.013). Conversely, the median predischARGE BNP concentration was not significantly different among patients with resolved congestion, residual congestion with improvement, and residual congestion without improvement (259 [IQR 123–484], 247 [IQR 113–484], and 345 [IQR 152, 561] pg/mL, respectively). We also evaluated other variables, including congestion scores and their constituents (Supplementary Table). Age and serum concentrations of blood urea nitrogen, creatinine, and BNP were greater in subjects with residual congestion and lesser improvement than in those with resolved congestion or residual congestion and higher improvement. However, the ratio of current or former smokers, the prevalence of hypertension, systolic blood pressure, and serum albumin, total cholesterol, and hemoglobin concentrations were lower in subjects with residual congestion and lesser improvement.

Serial measurements in eGFR during first 3 days were available for 376 patients (83.0% of study subjects). The decline in eGFR >20% was slightly greater in subjects with residual congestion than in those with removed congestion. Given the possibility of B-type natriuretic peptide (BNP)-guided therapy, we evaluated BNP concentrations across the 3 groups (Supplementary Table). The median admission BNP concentration (pg/mL) was 599 (IQR 259–1,046), 627 (IQR 316–1,033), and 694 (IQR 415–1,482) for patients with resolved congestion, residual congestion with improvement, and residual congestion without improvement, respectively (P=0.013). Conversely, the median predischARGE BNP concentration was not significantly different among patients with resolved congestion, residual congestion with improvement, and residual congestion without improvement (259 [IQR 123–484], 247 [IQR 113–484], and 345 [IQR 152, 561] pg/mL, respectively). We also evaluated other variables, including congestion scores and their constituents (Supplementary Table). Age and serum concentrations of blood urea nitrogen, creatinine, and BNP were greater in subjects with residual congestion and lesser improvement than in those with resolved congestion or residual congestion and higher improvement. However, the ratio of current or former smokers, the prevalence of hypertension, systolic blood pressure, and serum albumin, total cholesterol, and hemoglobin concentrations were lower in subjects with residual congestion and lesser improvement.

Serial measurements in eGFR during first 3 days were available for 376 patients (83.0% of study subjects). The decline in eGFR >20% was slightly greater in subjects with residual congestion than in those with removed congestion.

| Table 3. Congestion Scores According to Mortality at 1 Year |
|---------------------------------------------------------------|
| All patients (n=453) | Dead at 1 year (n=103) | Alive at 1 year (n=350) | P-valueA |
| Congestion score | | | |
| At admission (points) | 11 (8–14) | 11 (8–14) | 11 (8–14) | 0.346 |
| On Day 3 (points) | 2 (1–5) | 4 (1–7) | 2 (0–4) | <0.001* |
| ≥3 points (%) | 46.6 | 66.0 | 40.9 | <0.001* |
| At discharge (points) | 0 | 0 (0–1) | 0 | 0.065 |
| ≥3 points (%) | 3.9 | 4.9 | 3.7 | 0.654 |
| % Reduction in scoresB | 77.8 (50.0–92.9) | 58.3 (33.3–85.7) | 81.3 (571–100) | <0.001* |
| Reduction in scoresB (points) | 7 (4–11) | 6 (4–9) | 8 (4–11) | 0.009* |
| Rate of improvementB (%) | 65.1 | 43.7 | 71.4 | <0.001* |

Continuous variables are given as the median (interquartile range). A-P-values are for comparisons between subjects who were alive at 1 year and those who had died. B-From admission to Day 3. *P<0.05.

| Table 4. Predictors for Mortality at 1 Year According to Cox Regression Analysis |
|-----------------------------------------------|
| All-cause mortality | Univariate | Multivariate | Cardiovascular mortality |
| Age | 1.05 (1.03–1.07) | <.001* | 1.05 (1.02–1.08) | <.001* |
| BMI | 0.91 (0.86–0.95) | <.001* | 0.91 (0.85–0.97) | 0.002* |
| SBP | 0.99 (0.99–1.00) | 0.001* | 0.99 (0.98–1.00) | 0.002* |
| Potassium | 1.45 (1.15–1.79) | 0.002* | 1.63 (1.26–2.05) | <.001* |
| Albumin | 0.53 (0.37–0.77) | 0.001* | 0.53 (0.35–0.83) | 0.005* |
| Anemia | 1.76 (1.34–2.41) | <.001* | 4.10 (1.88–8.95) | <.001* |
| LVEF | 0.97 (0.95–0.98) | <.001* | 3.15 (1.37–7.27) | 0.007* |
| Ischemic | 1.52 (1.25–1.84) | <.001* | 0.97 (0.95–0.98) | <.001* |
| Previous HF hospitalization | 1.33 (1.09–1.61) | 0.004* | 2.40 (1.51–3.81) | 0.001* |
| Hypertension | 0.70 (0.58–0.85) | <.001* | 1.97 (1.24–3.13) | 0.004* |
| Rate of improvementB (%) | 65.1 | 43.7 | 71.4 | <0.001* |

CI, confidence interval; HR, hazard ratio. Other abbreviations as in Table 1. *P<0.05.
The results of the present study indicate that residual congestion at Day 3 or lesser improvement from admission to Day 3 are both associated with increased 1-year mortality in patients with acute decompensated HF. Furthermore, both residual congestion and lesser improvement in congestion scores become prognostic values after adjusting for (18.1% vs. 17.6%), but the difference was not statistically significant (P=0.893). Multivariable logistic regression analysis revealed that albumin concentration and the prevalence of anemia were significantly and independently associated with the presence of residual congestion (ORs 1.60 [95% CI 1.02–2.49; P=0.002] and 0.63 [95% CI 0.40–0.98; P=0.040], respectively).

**Figure 2.** Survival curves for (A) 1-year all-cause mortality and (B) cardiovascular mortality according to left ventricular ejection fraction (LVEF).

**Table 5.** Predictive Value of Congestion Scores on Day 3 and Improvement in Congestion Scores for 1-Year Mortality and Rehospitalization Due to HF According to Cox Regression Analysis

|                          | Not adjusted | Adjusted<sup>a</sup> |          |          |
|--------------------------|--------------|-----------------------|----------|----------|
|                          | HR (95% CI)  | P-value               | HR (95% CI) | P-value |
| All-cause mortality      |              |                       |          |          |
| Score on Day 3 ≥3 points | 2.68 (1.78–4.03) | <0.001*               | 1.76 (1.07–2.80) | 0.024*   |
| Improvement <64%         | 3.04 (2.06–4.49) | <0.001*               | 2.21 (1.37–3.57) | 0.001*   |
| Score on Day 3 <3 points | Ref.         | <0.01<sup>b</sup>     | Ref.      | <0.01<sup>b</sup> |
| Score on Day 3 ≥3 points with ≥64% improvement | 1.23 (0.64–2.50) | 0.496 | 0.93 (0.44–1.97) | 0.848 |
| Score on Day 3 ≥3 points with <64% improvement | 3.21 (2.10–4.90) | <0.001* | 2.17 (1.30–3.63) | 0.003*   |
| Cardiovascular mortality |              |                       |          |          |
| Score on Day 3 ≥3 points | 3.76 (2.22–6.35) | <0.001*               | 2.41 (1.29–4.50) | 0.006*   |
| Improvement <64%         | 4.31 (2.65–7.01) | <0.001*               | 3.14 (1.72–5.74) | <0.001*   |
| Score on Day 3 <3 points | Ref.         | <0.01<sup>b</sup>     | Ref.      | <0.01<sup>b</sup> |
| Score on Day 3 ≥3 points with ≥64% improvement | 1.51 (0.63–3.62) | 0.354 | 1.04 (0.38–2.88) | 0.933 |
| Score on Day 3 ≥3 points with <64% improvement | 4.76 (2.76–8.21) | <0.001* | 3.17 (1.65–6.11) | <0.001*   |
| Heart failure readmission |              |                       |          |          |
| Score on Day 3 ≥3 points | 0.148        |                       |          |          |
| Improvement <64%         | 0.467        |                       |          |          |

<sup>a</sup>For all-cause mortality, adjusted for age, BMI, SBP, potassium and albumin concentrations, the prevalence of anemia and hypertension, LVEF, ischemic etiology, and previous HF hospitalization; for cardiovascular mortality, adjusted for age, BMI, SBP, potassium and albumin concentrations, the prevalence of anemia, hypertension, and reduced eGFR, LVEF, ischemic etiology, and previous HF hospitalization. These covariates were found to have P<0.05 by univariate Cox regression analysis (see Table 4).<sup>b</sup>P-values for trend. Abbreviations as in Tables 1, 4.

*P<0.05.

**Discussion**

The results of the present study indicate that residual congestion at Day 3 or lesser improvement from admission to Day 3 are both associated with increased 1-year mortality in patients with acute decompensated HF. Furthermore, both residual congestion and lesser improvement in congestion scores become prognostic values after adjusting for...
We also identified that rapid congestion improvement in patients was associated with a favorable prognosis, even if these patients had residual congestion on Day 3. Congestion has been shown to be associated with troponin levels and may lead directly to subclinical myocardial injury. Furthermore, subsequent pathways from congestion leading to adverse outcomes include elevated venous pressures that compromise the function of the kidney or other organs. Therefore, a rapid improvement in clinical signs, such as dyspnea, is desirable in patients hospitalized with acute decompensated HF. The results of this study may reflect the guideline-recommended and established strategy, consistent with prior observations. However, it is uncertain that the rapid relief of congestion, regardless of residual congestion, offers a favorable prognosis.

Clinical congestion was reported to be an important therapeutic target of management in the EVEREST trial. We recognize that the congestion score proposed in the EVEREST trial may be beneficial from the viewpoint of both subjective and objective values; thus, we determined this score serially in the present study. A composite congestion score at discharge or Day 7 has been identified as being independently associated with prognosis; however, serial changes during the acute phase during hospitalization were not described in that study. The comparison of results between the present study and the EVEREST trial is difficult because of differences in the severity of the index congestion (initial median congestion score 11 points in the present study vs. 4.1 points in the EVEREST trial), and the score at discharge (almost 0) was not associated with 1-year mortality in the present study, which may be due to the longer hospitalization period (median 16 days; IQR 11–24 days). Pang et al proposed a tool to evaluate congestion in patients with acute decompenated HF, namely the Provocative Dyspnea Assessment, a measurement method that combines sequential dyspnea provocation by positioning and walking. Pang et al also noted the need to measure symptom severity at each time point using the same measurement. However, it is difficult to use this assessment tool with all HF patients in real-world clinical practice. In addition, congestion assessment using the radiographic congestion score index has been important in predicting mid-term prognosis in HF patients.

Figure 3. Survival curves for (A) 1-year all-cause mortality and (B) cardiovascular mortality according to congestion status: resolved congestion, residual congestion with greater improvement, and residual congestion with lesser improvement.
Acknowledgment

The authors are grateful to the staff at Kasugai Municipal Hospital for their assistance collecting the medical data.

Conflict of Interest

T.M. is a member of Circulation Journal Editorial Team. The other authors declare no conflicts of interest.

Data Availability

Deidentified participant data will be shared on request to the corresponding author. All data will be shared, as will the study protocol. Data will be available from within 6 months after publication for a period of 1 year. Data will be shared after permission has been granted by the Committees on Ethics of Kasugai Municipal Hospital.

References

1. Okura Y, Ramadan MM, Ohno Y, Mitsuma W, Tanaka K, Ito M, et al. Impending epidemic: Future projection of heart failure in Japan to the year 2055. Circ J 2008; 72: 489–491.
2. Ushigome R, Sakata Y, Nochioka K, Miyata S, Miura M, Tadaki S, et al. Temporal trends in clinical characteristics, management and prognosis of patients with symptomatic heart failure in Japan: Report from the CHART Studies. Circ J 2015; 79: 2396–2407.
3. Dharmarajan K, Rich MW. Epidemiology, pathophysiology, and prognosis of heart failure in older adults. Heart Fail Clin 2017; 13: 417–426.
4. Gheorghiade M, Vaduganathan M, Fonarow GC, Bonow RO. Rehospitalization for heart failure: Problems and perspectives. J Am Coll Cardiol 2013; 61: 391–403.
5. Moita B, Marques AP, Camacho AM, Leão Neves P, Santana R. One-year rehospitalisations for congestive heart failure in Portuguese NHS hospitals: A multilevel approach on patterns of use and contributing factors. BMJ Open 2019; 9: e031346.
6. O’Connor CM, Miller AB, Blair JE, Konstam MA, Wedge P, Bahit MC, et al. Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) investigators. Causes of death and rehospitalization in patients hospitalized with worsening heart failure and reduced left ventricular ejection fraction: Results from Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study with Tolvaptan (EVEREST) program. Am Heart J 2010; 159: 841–849.
7. Gheorghiade M, Filippatos G, De Luca L, Burnett J. Congestion in acute heart failure syndromes: An essential target of evaluation and treatment. Am J Med 2006; 119(Suppl 1e): S3–S10.
8. Goldsmith SR, Brandimarte F, Gheorghiade M. Congestion as a therapeutic target in acute heart failure syndromes. Prog Cardiovasc Dis 2010; 52: 383–392.
9. Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JG, Coats AJ, et al. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association (HFA) of the ESC. Eur J Heart Fail 2016; 18: 891–975.
10. Ambrosy AP, Pang PS, Khan S, Konstam MA, Fonarow GC, Traver B, et al; EVEREST Trial Investigators. Clinical course and predictive value of congestion during hospitalization in patients admitted for worsening signs and symptoms of heart failure with reduced ejection fraction: Findings from the EVEREST trial. Eur Heart J 2013; 34: 835–843.
11. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Colvin MM, et al. 2017 ACC/AHA/HFSA focused update of the 2013 ACCF/AHA guideline for the management of heart failure: A report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Failure Society of America. Circulation 2017; 136: e137–e161.
12. Nutritional anaemias: Report of a WHO scientific group. World Health Organ Tech Rep Ser 1968; 405: 5–37.
13. Negi S, Sawano M, Kohsaka S, Inohara T, Shirashi Y, Kohno T, et al. Prognostic implication of physical signs of congestion in acute heart failure patients and its association with steady-state biomarker levels. PLoS One 2014; 9: e96325.
14. Mullens W, Abrahams Z, Francis GS, Sokos G, Taylor DO, Starling RC, et al. Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009; 53: 589–596.
15. Gheorghiade M, Konstam MA, Burnett JC Jr, Grinfeld L, Maggioni AP, Swedberg K, et al. Short-term clinical effects of tolvaptan, an oral vasopressin antagonist, in patients hospitalized for heart failure: The EVEREST Clinical Status Trials. JAMA 2007; 297: 1332–1343.
16. Pang PS, Cleland JG, Teerlink JR, Collins SP, Lindsell CJ, Sopko G, et al. Acute Heart Failure Syndromes International Working Group. A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: The need for a uniform approach. Eur Heart J 2008; 29: 816–824.
17. Kobayashi M, Watanabe M, Coiro S, Becker M, Paku Y, Iwasaki Y, et al. Mid-term prognostic impact of residual pulmonary congestion assessed by radiographic scoring in patients admitted for worsening heart failure. Int J Cardiol 2019; 289: 91–98.
18. Loghart D, Thabut G, Jourdain P, Chavelas C, Beyne P, Beauvais F, et al. Predischarge B-type natriuretic peptide assay for identifying patients at high risk of re-admission after decompensated heart failure. J Am Coll Cardiol 2004; 43: 635–641.

Supplementary Files

Please find supplementary file(s):
http://dx.doi.org/10.1253/circj.CJ-19-1128